


What is claimed is:

1. A method of enhancing an immune response in a subject to an antigen, the method comprising administering to a subject an antigen and an effective amount of a tryptanthrin compound, or a pharmaceutically acceptable salt thereof, to enhance the immune response to said antigen.
2. The method of claim 1, wherein the antigen is derived from a bacterial, parasitic, viral, or fungal pathogen.
3. The method of claim 2 wherein the bacterial pathogen is selected from the group consisting of diphtheria, staphylococcus, cholera, tuberculosis, tetanus, streptococcus pneumoniae, streptococcus agalactiae, streptococcus pyogenes, pertussis, Neisseria meningitis, Neisseria gonorrhoeae, chlamydia, Helicobacter pylori, and Hemophilus influenza type B.
4. The method of claim 2 wherein the viral pathogen is selected from the group consisting of viral meningitis, rhinovirus, influenza, respiratory syncytial virus, parainfluenza virus, rotavirus, tick borne encephalitis virus, coronaviridae, rhabodoviridae, VZV, EBV, CMV, HIV, HPV, HSV, HAV, HBV, HCV, and SARS.
5. The method of claim 2 wherein the parasitic pathogen is selected from the group consisting of Plasmodium falciparum, Plasmodium ovale, Plasmodium malariae, and P. vivax.
6. The method of claim 2, wherein the antigen is associated with a disease selected from the group consisting of BCG, cholera, plague, typhoid, hepatitis B infection, influenza, inactivated polio, rabies, measles, mumps, rubella, oral polio, yellow fever, tetanus, diphtheria, hemophilus influenzae b, meningococcus infection, tick borne encephalitis, SARS, HCV, HIV, and pneumococcus infection.
7. The method of claim 1 wherein the immune response is the cellular production of one or more cytokines.

8. The method of claim 1 wherein the tryptanthrin compound is a compound of Formula (I):



wherein

A, B, C, D, E, F, G, and H are independently selected from carbon and nitrogen, or A and B and/or C and D can be taken together to be nitrogen or sulfur;
R₁, R₂, R₃, R₄, R₈, and R₁₀ are independently selected from the group consisting of hydrogen, halogen, loweralkyl, alkyl, substituted alkyl, cycloalkyl, heterocyclyl, alkylheterocyclyl, substituted heterocyclyl, substituted alkenyl, amino, (substituted alkyl)(alkyl)amino, imino, haloloweralkyl, hydroxy, alkoxy, substituted alkoxy, hydroxyalkylthio, nitro, alkylsulfonyl, N-alkylsulfonamide, arylalkyl, arylalkylaryl, arylaryl, aryloxy, arylamino, acylamino, acyloxyamino, alkylaminoacylamino, alkylaminosulfonylamino, alkylamino, alkenylamino, dialkylamino, alkoxyalkylamino, alkoxyalkylheterocyclyl, mercaptoalkoxyalkyl, cyano, formyl, -COOR₁₁ wherein R₁₁ is hydrogen, loweralkyl, aryl, heterocyclyl, monosaccharide or disaccharide, and -CONR₁₂R₁₃ wherein R₁₂ and R₁₃ are independently selected from hydrogen, loweralkyl, aryl, heterocyclyl, saccharide, peptide and amino acid residues; or R₂ and R₃ taken together form a six membered aromatic ring;

R₇ and R₉ are independently selected from hydrogen, halogen, loweralkyl, haloloweralkyl, cycloalkyl, heterocyclyl, substituted heterocyclyl or heterocyclylalkyl; and

R₁, R₂, R₃, R₄, R₇, R₈, R₉, and R₁₀ are absent when the ring atom to which they would otherwise be bonded is sulfur or double-bonded nitrogen; or

a pharmaceutically acceptable salt,

provided that R₁, R₂, R₃, R₄, R₇, R₈, R₉, and R₁₀ are not all hydrogen when A, B, C, D, E, F, and H are carbon.


9. The method of claim 8,

wherein

A, B, C, D, E, F, G, and H are independently selected from carbon and nitrogen;

R₁, R₂, R₃, R₄, R₈ and R₁₀ are independently selected from the group consisting of hydrogen, halogen, loweralkyl, alkyl, substituted alkyl, heterocyclyl, substituted heterocyclyl, substituted alkenyl, (substituted alkyl)(alkyl)amino, haloloweralkyl, hydroxy, alkoxy, substituted alkoxy, hydroxyalkylthio, nitro, N-alkylsulfonamide, cyano, -COOR₁₁ wherein R₁₁ is hydrogen, loweralkyl, aryl, heterocyclyl, monosaccharide or disaccharide, and -CONR₁₂R₁₃ wherein R₁₂ and R₁₃ are independently selected from hydrogen, loweralkyl, aryl, heterocyclyl, saccharide, peptide and amino acid residues.

10. The method of claim 1 wherein the tryptanthrin compound is a compound of Formula (II):



wherein

D is carbon or nitrogen, and R₄ is absent when D is N;

R₁ is hydrogen, halogen, or loweralkyl;

R₂ is hydrogen or halogen;

R₃ is hydrogen, halogen, heterocyclyl, substituted heterocyclyl, (substituted alkyl)(alkyl)amino, or hydroxyalkylthio;

R₄ is hydrogen, halogen, alkoxy, substituted alkoxy, or hydroxy;

R₇ is hydrogen or haloloweralkyl;

R₈ is hydrogen, halogen, substituted alkoxy, haloloweralkyl, nitro, N-alkylsulfonamide, substituted alkenyl, substituted alkyl, COOR₁₁ wherein R₁₁ is loweralkyl, or -CONR₁₂R₁₃ wherein R₁₂ and R₁₃ are independently hydrogen or loweralkyl;

R₉ is hydrogen; and
R₁₀ is hydrogen, halogen, or loweralkyl;
or a pharmaceutically acceptable salt thereof.

11. The method of claim 1, wherein the tryptanthrin compound is selected from the group consisting of:

8-nitroindolo[2,1-b]quinazoline-6,12-dione,
3,8-difluoroindolo[2,1-b]quinazoline-6,12-dione,
10-fluoroindolo[2,1-b]quinazoline-6,12-dione,
1,8-difluoroindolo[2,1-b]quinazoline-6,12-dione,
8-fluoro-1-methylindolo[2,1-b]quinazoline-6,12-dione,
8,10-difluoroindolo[2,1-b]quinazoline-6,12-dione,
2,4-dibromo-1-fluoro-8-iodoindolo[2,1-b]quinazoline-6,12-dione,
2,4-dibromo-1-chloro-8-iodoindolo[2,1-b]quinazoline-6,12-dione,
2,4-dibromo-1-fluoroindolo[2,1-b]quinazoline-6,12-dione,
8-chloro-2-idoindolo[2,1-b]quinazoline-6,12-dione,
8-chloro-3-fluoroindolo[2,1-b]quinazoline-6,12-dione,
8-fluoro-4-hydroxyindolo[2,1-b]quinazoline-6,12-dione,
N-ethyl-4-(methyloxy)-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazoline-8-carboxamide,
3-fluoro-8-[(trifluoromethyl)oxy]indolo[2,1-b]quinazoline-6,12-dione,
3-[(2-hydroxyethyl)thio]-8-[(trifluoromethyl)oxy]indolo[2,1-b]quinazoline-6,12-dione,
pyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
9-fluoropyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
9-bromopyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
9-chloropyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
9-iodopyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
ethyl 5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indole-9-carboxylate,
N-octyl-5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indole-9-sulfonamide,
10-(trifluoromethyl)pyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
(5E)-6-(5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indol-9-yl)hex-5-enyl acetate,
6-(5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indol-9-yl)hexyl dihydrogen phosphate, and
9-[(trifluoromethyl)oxy]pyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
or a pharmaceutically acceptable salt thereof.


12. A pharmaceutical composition, comprising an antigen and a tryptanthrin compound.

13. The composition of claim 12, further comprising an aqueous carrier.

14. The composition of claim 12, wherein the antigen is associated with a disease selected from the group consisting of BCG, cholera, plague, typhoid, hepatitis B infection, influenza, inactivated polio, rabies, measles, mumps, rubella, oral polio, yellow fever, tetanus, diphtheria, hemophilus influenzae b, meningococcus infection, tick borne encephalitis, SARS, HCV, HIV, and pneumococcus infection.

15. The composition of claim 12, wherein the immune response is the cellular production of one or more cytokines.

16. The composition of claim 12, wherein the tryptanthrin compound is a compound of Formula I:



wherein

A, B, C, D, E, F, G, and H are independently selected from carbon and nitrogen, or A and B and/or C and D can be taken together to be nitrogen or sulfur;

R₁, R₂, R₃, R₄, R₈, and R₁₀ are independently selected from the group consisting of hydrogen, halogen, loweralkyl, alkyl, substituted alkyl, cycloalkyl, heterocyclyl, alkylheterocyclyl, substituted heterocyclyl, substituted alkenyl, amino, (substituted alkyl)(alkyl)amino, imino, haloloweralkyl, hydroxy, alkoxy, substituted alkoxy, hydroxyalkylthio, nitro, alkylsulfonyl, N-alkylsulfonamide, arylalkyl, arylalkylaryl, arylaryl, aryloxy, arylamino, acylamino, acyloxyamino, alkylaminoacylamino, alkylaminosulfonylamino, alkylamino, alkenylamino, dialkylamino, alkoxyalkylamino, alkoxyalkylheterocyclyl, mercaptoalkoxyalkyl, cyano, formyl, -COOR₁₁ wherein R₁₁ is hydrogen, loweralkyl, aryl, heterocyclyl, monosaccharide or disaccharide, and -CONR₁₂R₁₃ wherein R₁₂ and R₁₃ are independently selected from hydrogen, loweralkyl, aryl,

heterocyclyl, saccharide, peptide and amino acid residues; or R₂ and R₃ taken together form a six membered aromatic ring;

R₇ and R₉ are independently selected from hydrogen, halogen, loweralkyl, haloloweralkyl, cycloalkyl, heterocyclyl, substituted heterocyclyl or heterocyclylalkyl; and

R₁, R₂, R₃, R₄, R₇, R₈, R₉, and R₁₀ are absent when the ring atom to which they would otherwise be bonded is sulfur or double-bonded nitrogen; or

a pharmaceutically acceptable salt thereof,

provided that R₁, R₂, R₃, R₄, R₇, R₈, R₉, and R₁₀ are not all hydrogen when A, B, C, D, E, F, and H are carbon.


17. The composition of claim 16,

wherein

A, B, C, D, E, F, G, and H are independently selected from carbon and nitrogen;

R₁, R₂, R₃, R₄, R₈ and R₁₀ are independently selected from the group consisting of hydrogen, halogen, loweralkyl, alkyl, substituted alkyl, heterocyclyl, substituted heterocyclyl, substituted alkenyl, (substituted alkyl)(alkyl)amino, haloloweralkyl, hydroxy, alkoxy, substituted alkoxy, hydroxyalkylthio, nitro, N-alkylsulfonamide, cyano, -COOR₁₁ wherein R₁₁ is hydrogen, loweralkyl, aryl, heterocyclyl, monosaccharide or disaccharide, and -CONR₁₂R₁₃ wherein R₁₂ and R₁₃ are independently selected from hydrogen, loweralkyl, aryl, heterocyclyl, saccharide, peptide and amino acid residues.

18. The composition of claim 12, wherein the tryptanthrin compound is a compound of Formula II:



wherein

D is carbon or nitrogen, and R₄ is absent when D is N;

R₁ is hydrogen, halogen, or loweralkyl;

R₂ is hydrogen or halogen;

R₃ is hydrogen, halogen, heterocyclyl, substituted heterocyclyl, (substituted alkyl)(alkyl)amino, or hydroxyalkylthio;

R₄ is hydrogen, halogen, alkoxy, substituted alkoxy, or hydroxy;

R₇ is hydrogen or haloloweralkyl;

R₈ is hydrogen, halogen, substituted alkoxy, haloloweralkyl, nitro, N-alkylsulfonamide, substituted alkenyl, substituted alkyl, COOR₁₁ wherein R₁₁ is loweralkyl, or -CONR₁₂R₁₃ wherein R₁₂ and R₁₃ are independently hydrogen or loweralkyl;

R₉ is hydrogen; and

R₁₀ is hydrogen, halogen, or loweralkyl;

or a pharmaceutically acceptable salt thereof.


19. The composition of claim 12, wherein the tryptanthrin compound is selected from the group consisting of

8-nitroindolo[2,1-b]quinazoline-6,12-dione,
3,8-difluoroindolo[2,1-b]quinazoline-6,12-dione,
10-fluoroindolo[2,1-b]quinazoline-6,12-dione,
1,8-difluoroindolo[2,1-b]quinazoline-6,12-dione,
8-fluoro-1-methylindolo[2,1-b]quinazoline-6,12-dione,
8,10-difluoroindolo[2,1-b]quinazoline-6,12-dione,
2,4-dibromo-1-fluoro-8-iodoindolo[2,1-b]quinazoline-6,12-dione,
2,4-dibromo-1-chloro-8-iodoindolo[2,1-b]quinazoline-6,12-dione,
2,4-dibromo-1-fluoroindolo[2,1-b]quinazoline-6,12-dione,
8-chloro-2-iodoindolo[2,1-b]quinazoline-6,12-dione,
8-chloro-3-fluoroindolo[2,1-b]quinazoline-6,12-dione,
8-fluoro-4-hydroxyindolo[2,1-b]quinazoline-6,12-dione,
N-ethyl-4-(methyloxy)-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazoline-8-carboxamide,
3-fluoro-8-[(trifluoromethyl)oxy]indolo[2,1-b]quinazoline-6,12-dione,
3-[(2-hydroxyethyl)thio]-8-[(trifluoromethyl)oxy]indolo[2,1-b]quinazoline-6,12-dione,
pyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
9-fluoropyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
9-bromopyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
9-chloropyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
9-iodopyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
ethyl 5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indole-9-carboxylate,
N-octyl-5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indole-9-sulfonamide,
10-(trifluoromethyl)pyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,

(5E)-6-(5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indol-9-yl)hex-5-enyl acetate,
6-(5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indol-9-yl)hexyl dihydrogen phosphate, and
9-[(trifluoromethyl)oxy]pyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
or a pharmaceutically acceptable salt thereof.

20. A method of immunotherapy for the treatment of cancer, the method comprising administering to a subject an immunostimulatory effective amount of a tryptanthrin derivative.

21. The method of claim 20, wherein the tryptanthrin derivative is a compound of Formula II:



(II)

wherein


D is carbon or nitrogen, and R₄ is absent when D is N;
R₁ is hydrogen, halogen, or loweralkyl;
R₂ is hydrogen or halogen;
R₃ is hydrogen, halogen, heterocyclyl, substituted heterocyclyl, (substituted alkyl)(alkyl)amino, or hydroxyalkylthio;
R₄ is hydrogen, halogen, alkoxy, substituted alkoxy, or hydroxy;
R₇ is hydrogen or haloloweralkyl;
R₈ is hydrogen, halogen, substituted alkoxy, haloloweralkyl, nitro, N-alkylsulfonamide, substituted alkenyl, substituted alkyl, COOR₁₁ wherein R₁₁ is loweralkyl, or -CONR₁₂R₁₃ wherein R₁₂ and R₁₃ are independently hydrogen or loweralkyl;
R₉ is hydrogen; and
R₁₀ is hydrogen, halogen, or loweralkyl;

or a pharmaceutically acceptable salt thereof.

22. The method of claim 20, wherein the tryptanthrin derivative is selected from the group consisting of

8-nitroindolo[2,1-b]quinazoline-6,12-dione,
3,8-difluoroindolo[2,1-b]quinazoline-6,12-dione,
10-fluoroindolo[2,1-b]quinazoline-6,12-dione,
1,8-difluoroindolo[2,1-b]quinazoline-6,12-dione,
8-fluoro-1-methylindolo[2,1-b]quinazoline-6,12-dione,
8,10-difluoroindolo[2,1-b]quinazoline-6,12-dione,
2,4-dibromo-1-fluoro-8-iodoindolo[2,1-b]quinazoline-6,12-dione,
2,4-dibromo-1-chloro-8-iodoindolo[2,1-b]quinazoline-6,12-dione,
2,4-dibromo-1-fluoroindolo[2,1-b]quinazoline-6,12-dione,
8-chloro-2-iodoindolo[2,1-b]quinazoline-6,12-dione,
8-chloro-3-fluoroindolo[2,1-b]quinazoline-6,12-dione,
8-fluoro-4-hydroxyindolo[2,1-b]quinazoline-6,12-dione,
N-ethyl-4-(methyloxy)-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazoline-8-carboxamide,
3-fluoro-8-[(trifluoromethyl)oxy]indolo[2,1-b]quinazoline-6,12-dione,
3-[(2-hydroxyethyl)thio]-8-[(trifluoromethyl)oxy]indolo[2,1-b]quinazoline-6,12-dione,
pyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
9-fluoropyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
9-bromopyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
9-chloropyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
9-iodopyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
ethyl 5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indole-9-carboxylate,
N-octyl-5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indole-9-sulfonamide,
10-(trifluoromethyl)pyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
(5E)-6-(5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indol-9-yl)hex-5-enyl acetate,
6-(5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indol-9-yl)hexyl dihydrogen phosphate, and
9-[(trifluoromethyl)oxy]pyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
or a pharmaceutically acceptable salt thereof.

23. A kit comprising a compound of the Formula I,



wherein

A, B, C, D, E, F, G, and H are independently selected from carbon and nitrogen, or A and B and/or C and D can be taken together to be nitrogen or sulfur;

R₁, R₂, R₃, R₄, R₈, and R₁₀ are independently selected from the group consisting of hydrogen, halogen, loweralkyl, alkyl, substituted alkyl, cycloalkyl, heterocyclyl, alkylheterocyclyl, substituted heterocyclyl, substituted alkenyl, amino, (substituted alkyl)(alkyl)amino, imino, haloloweralkyl, hydroxy, alkoxy, substituted alkoxy, hydroxyalkylthio, nitro, alkylsulfonyl, N-alkylsulfonamide, arylalkyl, arylalkylaryl, arylaryl, aryloxy, arylamino, acylamino, acyloxyamino, alkylaminoacylamino, alkylaminosulfonylamino, alkylamino, alkenylamino, dialkylamino, alkoxyalkylamino, alkoxyalkylheterocyclyl, mercaptoalkoxyalkyl, cyano, formyl, -COOR₁₁ wherein R₁₁ is hydrogen, loweralkyl, aryl, heterocyclyl, monosaccharide or disaccharide, and -CONR₁₂R₁₃ wherein R₁₂ and R₁₃ are independently selected from hydrogen, loweralkyl, aryl, heterocyclyl, saccharide, peptide and amino acid residues; or R₂ and R₃ taken together form a six membered aromatic ring;

R₇ and R₉ are independently selected from hydrogen, halogen, loweralkyl, haloloweralkyl, cycloalkyl, heterocyclyl, substituted heterocyclyl or heterocyclalkyl; and

R₁, R₂, R₃, R₄, R₇, R₈, R₉, and R₁₀ are absent when the ring atom to which they would otherwise be bonded is sulfur or double-bonded nitrogen; or

a pharmaceutically acceptable salt thereof,
provided that R₁, R₂, R₃, R₄, R₇, R₈, R₉, and R₁₀ are not all hydrogen when A, B, C, D, E, F, and H are carbon;

one or more containers;

one or more antigens; and

optionally a delivery device for the compound and the antigen.

24. The kit of claim 23 wherein the delivery device is a syringe.
25. The kit of claim 23 wherein the delivery device is a nasal inhaler.
26. The kit of claim 23 wherein the delivery device is a transdermal patch.
27. The kit of claim 23 wherein the antigen and the compound are present in the same container.
28. The kit of claim 23 comprising a first container and a second container wherein the first container contains the compound and the second container contains the antigen.
29. The kit of claim 28 wherein the first container contains a second antigen.
30. The kit of claim 23 further comprising a non-tryptantrin adjuvant.
31. A small molecule immune potentiating compound selected from the group consisting of:
2,4-dibromo-8-iodoindolo[2,1-b]quinazoline-6,12-dione,
8-chloro-10-methylindolo[2,1-b]quinazoline-6,12-dione,
1,1-dimethylethyl 4-(2-fluoro-8-ido-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-3-yl)piperazine-1-carboxylate,
2,4-dibromo-1-fluoro-8-idoindolo[2,1-b]quinazoline-6,12-dione,
2,4-dibromo-1-chloro-8-idoindolo[2,1-b]quinazoline-6,12-dione,
2,4-dibromo-1-fluoroindolo[2,1-b]quinazoline-6,12-dione,
8-chloro-2-idoindolo[2,1-b]quinazoline-6,12-dione,
8-fluoro-4-hydroxyindolo[2,1-b]quinazoline-6,12-dione,
N-ethyl-4-(methyloxy)-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazoline-8-carboxamide,
8-[(trifluoromethyl)oxy]indolo[2,1-b]quinazoline-6,12-dione,
3-fluoro-8-[(trifluoromethyl)oxy]indolo[2,1-b]quinazoline-6,12-dione,
9-iodopyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
N-octyl-5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indole-9-sulfonamide,
10-(trifluoromethyl)pyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
diethyl (5E)-6-(5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indol-9-yl)hex-5-enylphosphonate,
(5E)-6-(5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indol-9-yl)hex-5-enylacetate,

9-(trifluoromethyl)pyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
6-(5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indol-9-yl)hexyl
dihydrogen phosphate,
9-[(trifluoromethyl)oxy]pyrido[2',3':4,5]pyrimido[1,2-a]indole-5,11-dione,
4-hydroxy-8-iodoindolo[2,1-b]quinazoline-6,12-dione,
2,4-dichloro-8-iodoindolo[2,1-b]quinazoline-6,12-dione,
2,8-diodoindolo[2,1-b]quinazoline-6,12-dione,
2,4,8-triiodoindolo[2,1-b]quinazoline-6,12-dione,
8-fluoro-4-[(phenylmethyl)oxy]indolo[2,1-b]quinazoline-6,12-dione,
8-chloro-3-morpholin-4-ylindolo[2,1-b]quinazoline-6,12-dione,
8-(trifluoromethyl)indolo[2,1-b]quinazoline-6,12-dione,
[(8-chloro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-3-
yl)(methyl)amino]acetic acid,
4-{{2-[(8-chloro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-3-
yl)(methyl)amino]ethyl}oxy}-4-oxobutanoic acid,
2-[(8-chloro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-3-
yl)(methyl)amino]ethyl octanoate,
3-[(2-hydroxyethyl)(methyl)amino]-8-[(trifluoromethyl)oxy]indolo[2,1-
b]quinazoline-6,12-dione,
8-chloro-3-[(2-hydroxyethyl)thio]indolo[2,1-b]quinazoline-6,12-dione, and
6-(5,11-dioxo-5,11-dihydropyrido[2',3':4,5]pyrimido[1,2-a]indol-9-yl)hexyl acetate,
or a pharmaceutically acceptable salt thereof.